Clinical Trial Update: SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) [Phase 2]

View source ↗

Summary

An update on a Phase 2 study evaluating SCIB1 and iSCIB1+ in melanoma patients treated with checkpoint inhibitors (nivolumab+ipilimumab or pembrolizumab).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• OPDIVO (nivolumab)
• SCIB1 (SCIB1)
• Yervoy (ipilimumab)
• iSCIB1+ (iSCIB1+)

Snippet

Sponsor: Scancell Ltd | Conditions: Malignant Melanoma, Melanoma (Skin) | Phase 2 | Status: ACTIVE_NOT_RECRUITING